Repository logo
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
    Communities & Collections
    Research Outputs
    Fundings & Projects
    People
    Organizations
    Statistics
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. College of Medicine /醫學院
  3. Institute of Medicine/醫學研究所
  4. Associations of the Expression Levels and Risk Variants of <i>CDKN2B‐AS1</i> Long Noncoding <scp>RNA</scp> With the Susceptibility and Progression of Prostate Cancer
 
  • Details
Options

Associations of the Expression Levels and Risk Variants of <i>CDKN2B‐AS1</i> Long Noncoding <scp>RNA</scp> With the Susceptibility and Progression of Prostate Cancer

Journal
Journal of Cellular and Molecular Medicine
Journal Volume
28
Journal Issue
23
ISSN
1582-1838
1582-4934
Date Issued
2024-12
Author(s)
Min‐Che Tung
Chia‐Yen Lin
Yu‐Ching Wen
Lun‐Ching Chang
Shun‐Fa Yang  
Ming‐Hsien Chien
DOI
10.1111/jcmm.70264
URI
https://scholars.csmu.edu.tw/handle/123456789/5119
Abstract
<jats:title>ABSTRACT</jats:title><jats:p>Genetic variants of deregulated long noncoding RNAs (lncRNAs) have been implicated in tumorigenesis, cancer progression and cancer recurrence. Single‐nucleotide polymorphisms (SNPs) of the lncRNA cyclin‐dependent kinase inhibitor 2B antisense RNA 1 (<jats:italic>CDKN2B‐AS1</jats:italic>) have been associated with the risk and progression of various cancers; however, their role in prostate cancer (PCa) remains underexplored. In this case–control study, we investigated the associations of <jats:italic>CDKN2B‐AS1</jats:italic> expression levels and variants with PCa risk and progression. For this, five SNPs of <jats:italic>CDKN2B‐AS1</jats:italic>—rs564398, rs1333048, rs1537373, rs2151280 and rs8181047—were genotyped using a TaqMan allelic discrimination assay; data were collected from 695 patients with PCa and 695 healthy controls. Our findings revealed that, under a dominant model, patients with PCa carrying at least one minor C allele of rs1333048 exhibited an increased risk of developing tumours with high Gleason grades; this risk was particularly high in patients without biochemical recurrence. Data from the Genotype‐Tissue Expression database indicated upregulated <jats:italic>CDKN2B‐AS1</jats:italic> expression in the prostates of individuals carrying the polymorphic C allele of rs1333048. Genotype screening of rs1333048 in PCa cell lines showed that cells with at least one minor C allele had higher <jats:italic>CDKN2B‐AS1</jats:italic> levels than those with the AA genotype. Furthermore, data from The Cancer Genome Atlas indicated that higher <jats:italic>CDKN2B‐AS1</jats:italic> levels in PCa tissues were correlated with larger tumour sizes (T3 + T4), more lymph node metastasis (N1), higher Gleason scores and shorter progression‐free survival. In conclusion, the polymorphic variants of <jats:italic>CDKN2B‐AS1</jats:italic> at rs1333048 may modulate <jats:italic>CDKN2B‐AS1</jats:italic> expression, thus accelerating PCa progression.</jats:p>
SDGs

[SDGs]SDG3

Publisher
Wiley
Type
journal-article
Make it your own

DSpace-CRIS can be extensively configured to meet your needs. Decide which information need to be collected and available with fine-grained security. Start updating the theme to match your Institution's web identity.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback